A blood test could help detect placenta accreta spectrum disorders early

Publicly released:
International

International researchers may have developed a blood test to detect life-threatening placenta accrete spectrum (PAS) disorders in mums-to-be. PAS disorders occur when the placenta grows too deeply into the wall of the uterus during pregnancy and fails to detach during childbirth. This can lead to severe haemorrhages and sometimes the mother’s death, and current methods to detect the conditions are not always conclusive or available. The team developed a chip which can detect cells that shed from the placenta in the blood of the mum-to-be; and increased levels could mean PAS. They tested 168 pregnant women who had previously been diagnosed with PAS, another placental condition, or normal placentation, and found these placental cells were higher in the blood of mums with PAS than mums without. While further research is needed, the team says this could lead to earlier detection of such disorders.

Media release

From: Springer Nature

1.  Medical research: Non-invasive method for detecting placenta accreta spectrum disorders

A method for the non-invasive and early detection of placenta accreta spectrum disorders (where the placenta grows too deeply into the wall of the uterus during pregnancy) is presented in Nature Communications this week. The findings may aid the early diagnosis of the disorders, which can lead to maternal deaths in childbirth.

Placenta accreta spectrum (PAS) disorders, including placenta accreta, placenta increta, placenta percreta, occur when the placenta grows too deeply into the wall of the uterus during pregnancy and then fails to detach following childbirth. This can cause severe hemorrhages, which may lead to maternal death in some instances. Current methods to detect the conditions, while effective, are not always conclusive or available in low resource settings.

Hsian-Rong Tseng, Yazhen Zhu, and colleagues optimize their previously developed NanoVelcro Chips, which contain thin, silicon nanowires coated with antibodies that detect circulating trophoblasts (cells that make up the placenta). These cells shed, as single or clustered cells, into the maternal blood circulation while the placenta is developing and an increase in their presence could indicate PAS. The authors tested the blood of 168 pregnant women who had previously been diagnosed with PAS, placenta previa (a condition where the placenta covers the cervix) or normal placentation. They found that the counts of single and clustered circulating trophoblasts were higher in the group with PAS than the other two groups. They also found that the number of single and clustered circulating trophoblasts can help to distinguish PAS from placenta previa and normal placentation, in early gestation.

The authors note that the further research is needed in larger samples but this method could, in the future, complement current techniques to improve diagnostic accuracy for placenta accreta spectrum disorders early in gestation.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Springer Nature, Web page The URL will go live after the embargo ends.
Journal/
conference:
Nature Communications
Research:Paper
Organisation/s: University of California, USA
Funder: This work was supported by National Institutes of Health (U01EB026421, R01CA246304, R01CA218356, R01CA253651, R21CA235340, R21CA240887, R01CA255727, and R01HD091773) as well as the Iris Cantor-UCLA Women’s Health Center Executive Advisory Board and NCATS UCLA CTSI Grant Number UL1TR000124. Following the management plan provide by UCLA Conflict of Interest Review Committee, Dr. Hsian-Rong Tseng would like to disclose that (i) he has a financial interest in CytoLumina Technologies Corp. and Pulsar Therapeutics Corp., and (ii) the UC Regents have licensed intellectual properties invented by Dr. Tseng to CytoLumina and Pulsar. The remaining authors declare no competing interests.
Media Contact/s
Contact details are only visible to registered journalists.